Th2 Cells

Th2 Cells


T helper type 2 (Th2) cells are a distinct lineage of CD4+ effector T cell that secretes IL-4, IL-5, IL-9, IL-13, and IL-17E/IL-25. These cells are required for humoral immunity and play an important role in coordinating the immune response to large extracellular pathogens. Th2 differentiation occurs in the presence of IL-4 and either IL-2, IL-7, or Thymic Stromal Lymphopoietin (TSLP).

Exposure of activated naive CD4+ T cells to IL-4 induces STAT6- dependent expression of GATA-3 and Growth Factor Independent-1 (GFI-1). GATA-3, the master transcriptional regulator of Th2 cells, promotes IL-5 and IL-13 expression, and along with GFI-1 stimulates the expansion of Th2 cells, while suppressing the differentiation of other T cell subtypes. In addition to IL-4-induced activation of GATA-3, IL-2, IL-7, or TSLP is required during Th2 differentiation to activate STAT5, which cooperates with GATA-3 to promote T cell production of IL-4. IL-4 regulates clonal expansion of Th2 cells, and along with IL-13, promotes B cell production of IgE and alternative macrophage activation. Other cytokines produced by Th2 cells stimulate eosinophil activation and survival (IL-5), or promote mast cell activation (IL-9). Under certain conditions, both IL- 17E/IL-25 and IL-33 have also been shown to initiate or enhance Th2-like immune responses. In addition to the production of specific cytokines, Th2 cells are characterized by the expression of the cell surface receptors, ST2/IL-1 R4, CXCR4, CCR3, CCR4, and CCR8. Excessive Th2-type immune responses have been implicated in the development of chronic allergic inflammation and asthma.


Comments

Post a Comment

Popular posts from this blog

article review on tocilizumab production

Tocilizumab (Actemra) is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, which is involved in the inflammatory response. It is used to treat rheumatoid arthritis, systemic juvenile idiopathic arthritis and other inflammatory conditions. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. One research article "Development of an efficient and scalable fed-batch culture process for the production of tocilizumab in Chinese hamster ovary cells" by Li et al. (2019) aimed to optimize the production of tocilizumab using a fed-batch cultivation system in CHO cells. The study aimed to improve the yield and quality of the protein, and to develop a process that can be easily scaled up for industrial production. The results of the study showed that the yield of tocilizumab was significantly improved by optimizing the culture conditions, such as the temperature, pH, and dissolved oxygen, as well as by using a specific
Read more

MOA OF AMINOGLYCOSIDE ANTIBIOTICS

Image
MOA                  of   Aminoglycoside             Antibiotics Aminoglycosides exert their bactericidal effect by inhibiting protein synthesis in bacteria and compromising the structure of the bacterial cell wall . Aminoglycoside Antibiotics Aminoglycoside antibiotics are used to treat serious infections caused by gram-negative bacteria . Some commonly used aminoglycosides include: amikacin (Amikin®); apramycin; capreomycin; gentamicin (Garamycin®); kanamycin (Kantrex®); neomycin (Mycifradin®); netilmicin (Netromycin®); paromomycin (Humatin®); streptomycin; tobramycin (TOBI Solution®, TobraDex®, Nebcin®) Mode of Action Although aminoglycosides stop bacteria from making proteins, it is uncertain whether this is the action that results in bacterial cell death.     Disruption of Protein Synthesis A minoglyco s i d e s b i n d to the b a c t er i al 3 0 S r i b o s o mal s ubunit. R i b o s om e s are the p ro t e i n
Read more

article review on adalimumab production

Adalimumab is a recombinant human monoclonal antibody that is used to treat a variety of inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. A research article "Development of a high-titer, high-density fed-batch process for the production of adalimumab in CHO cells" by Chen et al. (2018) aimed to improve the production of adalimumab by developing a high-titer and high-density fed-batch process. The study used a CHO cell line that had been modified to express the adalimumab gene. The cells were grown in a culture medium containing glucose, amino acids, and a proprietary feed supplement, and the culture conditions were optimized to achieve high yields of the protein. The results of the study showed that a high yield of adalimumab (over 2g/L) was achieved using the fed-batch cultivation system. The study also found that the specific productivity of th
Read more